, but the influence of UVA1 and UVA/narrowband UVB (UVBnb) phototherapy on serum vitamin D is unknown. OBJECTIVE: We sought to investigate the influence of UVBnb, UVA1, and UVA/UVBnb phototherapy on serum levels of 25(OH)D and related parameters in patients with an inflammatory skin condition. METHODS: 25(OH)D, as well as calcium, parathormone, phosphate, and albumin were measured before therapy, 2 weeks after start, and after completion of the phototherapy. Diagnoses were divided in 4 groups: atopic dermatitis, psoriasis, morphea, and others. RESULTS: We surveyed 116 dermatologic patients undergoing phototherapy with UVA1 (n = 38), UVA/UVBnb (n = 30), or UVBnb (n = 48) 2 to 3 times a week for 53 to 90 days. UVBnb phototherapy increased serum 25(OH)D from 22.1 to 39.5 ng/mL after the therapy (P < .001). The lower the baseline 25(OH)D level was, the steeper the increase in 25(OH)D was upon application of UVBnb phototherapy. UVA/UVBnb therapy also increased serum 25(OH)D, from 23.9 to 50.3 ng/mL (P = .003). Conversely, in the UVA1 therapy group, 25(OH)D serum levels decreased significantly from 21.9 to 19.0 ng/mL (P < .001). LIMITATIONS: The study design was open trial without randomization. An influence of a precise skin disease cannot be excluded because of the heterogeneous diagnoses. Bias may have arisen from patient preference for treatment at our center, referral, unrecognized differences in underlying skin disease, and other factors. 
Methods: 25(OH)D, as well as calcium, parathormone, phosphate and albumin were measured before therapy, two weeks after start as well as after completion of the phototherapy at week 12. Diagnoses were divided in four groups: atopic dermatitis, psoriasis, morphea and others.
Results:
We surveyed 116 dermatological patients undergoing phototherapy with UVA1 (n=38), UVA/UVBnb (n=29) or UVBnb (n=49) two to three times a week for 53-90 days.
UVBnb phototherapy increased serum 25(OH)D from 22.1 to 39.5ng/ml after the therapy (p<0.001). The lower the baseline 25(OH)D level was, the steeper the increase in 25(OH)D was upon application of UVBnb phototherapy. UVA/UVBnb therapy also increased serum 25(OH)D, from 23.9 to 50.3ng/ml (p=0.003). Conversely, in the UVA1 therapy group, 25(OH)D serum levels decreased significantly from 21.9 to 19.0ng/ml (p<0.001).
Limitations:
The study design: open randomized trial without randomization. An influence of a precise skin disease cannot be excluded because of the heterogeneous diagnoses. Bias may have arisen from patient preference for treatment at our center, from referral, from unrecognized differences in underlying skin disease and other factors. 
INTRODUCTION
Phototherapy with ultraviolet light is a safe and effective treatment for a variety of inflammatory skin diseases. After replacing the broadband UVB (280-320 nm), narrowband UVB (311 nm) has become the first-line phototherapy due to its high efficacy and safety. UVB phototherapy has been shown to increase serum 25(OH) D concentrations in several studies. 1, 2 In the last decade, ultraviolet A1 (UVA1, 340-400nm) phototherapy has emerged as a therapeutic modality in sclerosing and inflammatory skin conditions, and vitamin D has been identified as important mediator in inflammatory skin disease. 3 No data is available on vitamin D level variations under UVA1 phototherapy. A randomized controlled trial showed a significant increase in 25(OH)D serum levels after use of sunbeds emitting 0.5% and 1.4% UVB. 4 A significant increase in 25(OH)D had also been described after use of UVA sunbeds emitting only 0.36% of UVB.
5
Although the action spectrum for the conversion of 7-dehydrocholesterol to vitamin D3 is thought to be within the UVB range (280-320 nm), these results suggest that the higher wavelengths of UVA (320-400 nm) may as well have an effect. Nevertheless, the possibility that the small amounts of UVB emitted by these lamps might explain the increase either alone or in combination with UVA has not been ruled out. We investigated the serum levels of 25(OH)D under UVBnb, UVA/UVBnb and UVA1 phototherapy.
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MATERIALS AND METHODS
Design
An open observational study was conducted at Zurich University Hospital, Zurich, 
Patients
Weight and height were recorded and the body mass index (BMI) was calculated. The inclusion criteria were: Adult patients with a skin disease and the dermatological indication for a phototherapy with UVBnb, UVA/UVBnb or UVA1 as well as oral and written informed consent. The phototherapy was chosen according to the skin disease (for example psoriasis is treated with UVBnb, morphoea with UVA1; cf. Table 3 ).
Participants were excluded from for the study if they did not complete the phototherapy, had a break of 2 weeks or more in the phototherapy course, or withdrew their consent to participate ( Figure 1 ). Diagnosis groups were defined as follows: morphea/scleroderma (group 1), atopic dermatitis (group 2), psoriasis (group 3) and other (group 4) ( Table 3) . order to disclose differences in means of a continuous variable between two groups. In order to investigate differences in a continuous variable with respect to discrete factor with more than two levels, the one-way ANOVA together with the Scheffé post-hoc test 
Definition of vitamin D sufficiency
Clinical evaluation
Clinical examination of the skin was performed on day 0, day 14 and at completion of therapy at about 12 weeks.
Laboratory measurements
Serum 25(OH)D, as well as plasma levels of calcium, parathormone, phosphate, albumin and CRP levels were measured at day 0, day 14 and at completion of therapy at about 12 weeks. Calcium level was corrected with albumin level.
Study completion
7
A patient was considered to have completed the study after visit 3 and the last blood sampling.
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RESULTS
Of 126 screened patients, eight refused to participate or were not included because they could not complete phototherapy in our phototherapy unit. participants completed the study (Figure 1 ). Reasons for dropouts were loss to follow-up in 31 patients and exclusion in one patient because phototherapy was changed to PUVA-therapy.
Population parameters before therapy
The age was similar across all therapy groups (p= 0.905). The baseline 25(OH)D level was comparable in all 3 groups before therapy as well as between the different diagnosis groups (p= 0.851).
Influence of phototherapy on 25(OH)D concentrations
Serum levels of 25(OH)D increased under UVBnb therapy, from 22.1 (+/-10.3) to 39.5
(+/-12.2) ng/ml (increase 18.6 +/-4.6 ng/ml; p<0.001). This effect was already detectable after 2 weeks of phototherapy (p<0.001) (Figure 2a, Figure 2b , Table 2 Before therapy with UVBnb there were eight insufficient (<20 ng/ml) and five deficient (<10 ng/ml) patients, and only two showed an insufficiency after therapy (no deficiency).
In the UVA/UVBnb group, there were five insufficient and four deficient patients before therapy and only one insufficient patient after therapy (no deficient ones), respectively. In the UVA1 group, 14 patients had an insufficient 25(OH)D serum level and one was deficient in 25(OH)D. After UVA1 therapy, we detected 15 insufficient and five deficient patients.
Influence of gender on serum vitamin D level
No gender difference was observed in any single treatment group.
Influence of season on serum vitamin D level
Blood samples taken in winter and spring were grouped together as "winter"(w), in summer and fall grouped together as "summer"(s). Patients were then classified into 4 different groups, depending on when they had the 1 st and the 2 nd blood sampling (w-w, w-s, s-w, s-s). Before therapy, the vitamin D serum level was significantly lower in the winter group (p = 0.012, 
Influence of phototherapy on the other parameters
The plasma levels of albumin-corrected calcium, phosphate, parathormone and CRP
were not influenced by any of the phototherapies. Changes in systolic and diastolic blood pressure were not correlated to 25(OH)D serum level change. BMI, age and diagnosis were neither correlated to serum 25(OH)D change nor to phototherapy used.
We did not observe any correlation between age and vitamin D synthesis (p values in Table 1 ).
Quality of life and phototherapy
DLQI improved in the total patients' collective (p<0.001), as well as in each phototherapy group considered separately, however, we could not detect a difference between the phototherapy groups. DLQI did not correlate with the change in the vitamin D serum level.
DISCUSSION
Our study confirms the results of previous studies showing that UVBnb phototherapy increases serum vitamin D levels. In a case series of women with psoriasis, UVB broadband treatment for 8-12 weeks increased serum levels of 25(OH)D 1.62-fold from base level. 8 Almost all studies were performed with UVB broadband and only seven recent studies investigated the plasmatic increase of vitamin D under UVBnb.
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Czarnecki et al. showed that one oral dose of 50'000 IU of cholecalciferol raised the serum level by 3.5 mmol/l on average, which was similar to the effect of one dose of UVBnb to the entire body surface. 13 Only one study observed a vitamin D increase in the plasma under psoralen-UVA therapy, however the authors could not exclude a role for the small amount of UVB emitted by the lamp. 16 Our observation that individuals with low initial concentrations of 25(OH)D have a higher response to UVBnb irradiation confirmed previous reports. 4, 11, 17 We did not find any correlation between the cumulative dose of UVBnb and the increase of serum 25(OH)D at 12 weeks, in accordance with Osmancevic et al. 14 but in contradiction to a recent study. 18 The explanation might be that 25(OH)D reaches a plateau after 3 weeks already, and that exposure to additional UVBnb may not result in a continued proportional increase in serum vitamin D. UVBnb therapies but significant only under UVBbb therapy. 8, 12, 14 However we cannot exclude a significant PTH decrease with a greater patient number, as we observe a tendency towards a reduction of plasmatic PTH.
Krause et al. showed that serial whole-body irradiation with an artificial UVB source, in contrast to a UVA source, could reduce blood pressure in patients with untreated mild hypertension. 21 In our study, no change in systolic and diastolic blood pressure could be correlated with 25(OH)D levels, but our population was normotensive. The ability to synthesize vitamin D decreases with age. 22 We were not able to observe any correlation between age and vitamin D synthesis, in line with other previous studies. 8, 12, 21 We observed also no relationship between BMI and vitamin D change, confirming the results of previous studies. 6, 23 Diagnosis was neither correlated to the extent of serum vitamin D change nor to phototherapy modality. It has been shown that the UVBnb course 13 increases 25(OH)D in the healthy subject similarly to the patients with psoriasis and atopic dermatitis 9 , implying that inflamed skin is also able to produce 25(OH)D under the influence of UVBnb.
Missing data hampered the analysis of the quality of life index in our study: complete information (DLQI before and after therapy) was available for 25 patients only. DLQI data was sufficiently complete, however, to document an increase in health related quality of life along phototherapy, while the number of completed questionnaires may limit the observed lack of correlation to serum vitamin D changes.
The strength of our study is the prospective design with standardized treatments and blood analysis. Among the main limitations of the study is the study design: this open randomized trial may be biased compared to a randomized controlled trial. Moreover, the type of phototherapy was chosen according to the dermatological diagnosis, excluding randomization. The different therapy groups are composed of heterogeneous diagnoses, and an influence of a precise skin disease cannot be excluded. Bias may have arisen from patient preference for treatment at our center, from referral, from unrecognized differences in underlying skin disease and other factors. The basal vitamin D level was comparable, independent of the diagnosis, but we cannot rule out a possible effect of different skin diseases on the individual susceptibility to UVA and/or UVB. 
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